CytomX delivers a pancreatic surprise
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
